BPC
NTLA icon

Bryce Point Capital’s Intellia Therapeutics NTLA Stock Holding History

Bryce Point Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,083
Closed -$304K – 366
2024
Q4 		$304K Buy
+26,083
New +$407K 0.09% 394

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bryce Point Capital's NTLA Position: Q1 2025 in Review

Bryce Point Capital sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 26,083 shares — an estimated $304K sold.

Bryce Point Capital first reported a position in NTLA in Q4 2024 and held it in 1 quarter. The position peaked at $304K in Q4 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Bryce Point Capital reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 26,083 Intellia Therapeutics shares in Q1 2025, an estimated $304K.
  • Bryce Point Capital first reported a position in Intellia Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Intellia Therapeutics position peaked at $304K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.